#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Brain injury Arginase deficiency Vitamin B12 deficiency Castleman's disease Small intestine leiomyosarcoma Liposarcoma Deafness neurosensory Kaposi's sarcoma Chondrosarcoma Epidermolysis bullosa Osteochondrodysplasia Loeys-Dietz syndrome Palmoplantar pustulosis Oesophageal atresia Small intestine neuroendocrine tumour More trials…

    Learn about Rare Diseases

    Retinoblastoma – Treatment Advanced systemic mastocytosis – Life with Disease Osteosarcoma recurrent – Life with Disease Pleomorphic leiomyosarcoma – Life with Disease Waldenstrom’s macroglobulinaemia refractory – Treatment Netherton’s syndrome – Basic Information Hereditary optic atrophy – Life with Disease Testicular leiomyosarcoma – Diagnostics Behcet’s syndrome – Life with Disease Undifferentiated sarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pramlintide Acetate Venlafaxine Sodium Iotalamate (125I) Etoposide Apadamtase Alfa Ep262 Vigabatrin Rivaroxaban Sorafenib Itraconazole Avalglucosidase Alfa Recombinant Interferon Beta-1B Betamethasone Acetate Treg02 Naloxone Hydrochloride Annamycin Lovo-A Elafibranor TIL CELLS Ion440 More therapies…

    Learn about Your Condition

    Ovarian cancer Follicular lymphoma stage III Hepatic neoplasm Insomnia Corneal graft rejection Netherton's syndrome Rheumatic disorder Oesophagogastroscopy Hyperoxaluria H1N1 influenza Type 2 diabetes mellitus Colon cancer stage IV Aortic stenosis Leukoencephalopathy Prodromal Alzheimer's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mjxyjg Ztvgrbaq Knegj 2jm Djspwibdn 4aulu Hvdlxnx

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • Tafasitamab
    • Lenalidomide
    Bulgaria Croatia Czechia Denmark Finland Hungary +4

  • Study on Vilobelimab and Drug Combination for Treating Ulcerative Pyoderma Gangrenosum in Adults

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Pyoderma gangrenosum
    Investigated Drugs:
    • Cortisone Acetate
    • Triamcinolone
    • Vilobelimab
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cervix carcinoma
    Investigated Drugs:
    • Dextran 70
    • Tisotumab Vedotin
    • Hypromellose
    Austria Belgium Czechia Finland France Germany +7

  • Study on the Effects and Safety of Dupilumab for Children Aged 2 to Under 6 with Uncontrolled Asthma or Severe Asthmatic Wheeze

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Wheezing
    • Asthma
    Investigated Drugs:
    • Fluticasone
    • Ipratropium Bromide
    • Salmeterol
    Czechia France Germany Greece Hungary Italy +3

  • Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Deucravacitinib
    • Apremilast
    Belgium Czechia Germany Hungary Poland Spain

  • Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    Bulgaria Croatia Czechia France Germany Greece +6

  • Study of GS-5245 for Treating COVID-19 in Children and Adolescents

    Not recruiting

    4 1 1
    Investigated Drugs:
    • Gs-5245
    Bulgaria Hungary Italy Poland Spain

  • Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Pembrolizumab
    • Sunitinib
    Czechia France Germany Hungary Ireland Poland +1

  • Study on the Effectiveness and Safety of SAR441566 for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Sar441566
    Bulgaria Czechia Germany Hungary Poland Portugal +1

  • Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    France Germany Hungary Italy Poland Spain
Previous Page
1 … 43 44 45 46 47 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!